Sammenfattende har indehaveren af markedsføringstilladelsen slettet indikationen for intravesikal anvendelse og for pancreascancer, der er refraktær over for 5- FU, mens indikationen for ovariecancer er begrundet.
In summary the MAH has deleted the indication for intravesical use and for 5-FU- refractory pancreatic cancer while the indication in ovarian cancer has been justified.